Covid Led to Closer Work Between FDA, Pharma, Genentech CEO Says

Close collaboration between U.S. drugmakers and regulators in the pandemic is speeding the way for new therapies in other areas including Alzheimer’s disease, the head of Roche Holding AG’s Genentech unit said.

The Food and Drug Administration’s flexibility in terms of data submission and clinical trials endpoints “offers so much possibility to bring treatments, meaningful treatments, to patients sooner,” Genentech Chief Executive Officer Alexander Hardy said Monday in an interview with Bloomberg Television from the HLTH conference in Boston.